4.5 Article

Adjunctive Use of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents: A Prospective, Open Pilot Study

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 72, 期 9, 页码 1263-1269

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m07003

关键词

-

资金

  1. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  2. National Institutes of Health/the National Institute of Mental Health (NIMH)
  3. National Institute on Drug Abuse
  4. National Institute of Neurological Disorders and Stroke
  5. National Institute on Aging
  6. NARSAD
  7. Stanley Foundation
  8. Cyberonics
  9. Neuronetics (past)
  10. St Jude Medical (Advanced Neuromodulation Systems)
  11. Magstim
  12. Brainsway
  13. Otsuka
  14. Neuronetics
  15. Sunovion
  16. AstraZeneca
  17. NIMH
  18. Eli Lilly
  19. Forest
  20. GlaxoSmithKline
  21. Somerset
  22. American Academy of Child and Adolescent Psychiatry/Eli Lilly
  23. Department of Psychiatry and Psychology, Mayo Clinic
  24. Stanley Medical Research Institute Center

向作者/读者索取更多资源

Objective: Depression is often a serious and debilitating illness in adolescents. Unfortunately, a significant number of adolescents do not respond to antidepressant medications or psychotherapy. Repetitive transcranial magnetic stimulation (rTMS) is a novel treatment intervention shown to benefit depression in adults, This study considered rTMS as an adjunctive treatment in adolescents with major depressive disorder. Method: This prospective, open, multicenter trial of active adjunctive rTMS was conducted with 8 adolescents with DSM-IV-TR major depressive disorder (MDD) that had not responded sufficiently to 2 adequate antidepressant medication trials. All subjects were maintained on a stable dose of a selective serotonin reuptake inhibitor during the trial. Thirty daily rTMS treatments were given 5 days per week over 6 to 8 weeks, rTMS was applied to the left dorsolateral prefrontal cortex (120% of motor threshold; 10 Hz; 4-second trains; 26-second intertrain interval; 75 trains) for a total of 3,000 stimulations per treatment session. Results: Seven of 8 adolescents completed all 30 treatments. rTMS was well tolerated, and no significant safety issues were identified. Suicidal ideation was present at baseline in 3 of the adolescents, and it improved during treatment. The primary outcome measure was the Children's Depression Rating Scale-Revised (CDRS-R); results improved significantly from baseline (mean [SD]) (65.9 [6.6]) to treatment 10(50.9 [12]), P <.02. The CDRS-R scores continued to improve through the rTMS treatment series at treatment 20 (40.1 [14]), P <.01; treatment 30 (32.6 [7.3]), P <.0001; and at 6-month follow-up (32.7 [3.8]), P <.0001. Conclusions: This prospective open trial suggests that rTMS is a safe, feasible, and potentially effective adjunctive therapy for treatment-resistant MDD in adolescents. Trial Registration: clinicaltrials.gov Identifier: NCT00587639 J Clin Psychiatry 2011;72(9):1263-1269 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据